Life Sciences
Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.
The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.
We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies.
Explore our sectors
Meet our lawyers
News and insights
Publications: 10 January 2023
The EU and UK adopt further sanctions against Russia
At the close of 2022, and with the war in Ukraine entering its tenth month, the EU and the UK adopted further sanctions packages against Russia. The latest sanctions packages include further asset…
Blog Post: 04 January 2023
Why AI drug discovery deals are different from traditional pharma collaborations
Pharma companies have been working with artificial intelligence (AI) for a decade or more. As the cost and time of bringing a new drug to market continues to rise, pharma companies are increasingly…
Publications: 20 December 2022
Why AI drug discovery deals are different from traditional pharma collaborations
Pharma companies have long collaborated with other organisations to bring new drugs to market. But what happens when their partner is an artificial intelligence (AI) company rather than another pharma…
Publications: 09 December 2022
What corporate data tells us about future M&A activity
We track a range of metrics to assess the likelihood of future deal activity across sectors. This analysis points to hotspots of M&A in tech, consumer, life sciences and possibly mining in the year to…
Recognition
I have used Allen & Overy for coordinating EU cases. They have extensive knowledge of coordinating litigation.
Clients quoted in Chambers Global 2021 (Life Sciences: Global-wide)
They are well equipped to explain and navigate the different local jurisdictions to help towards a better understanding of various markets.
Client quoted in Chambers Europe 2021 (Intellectual Property: Europe-wide)
Strong European offering with noted expertise in IP and patent litigation matters. Well regarded for its impressive client portfolio, which spans the pharmaceutical, biotechechnology, medtech, diagnostics and healthcare industries. Also offers impressive expertise in commercial transactions and M&A.
Chambers Global 2018 (Life Sciences: Global-wide)
Related links
Life Sciences Hub
We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.
Read moreCRISPR microsite
The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.
Go to micrositeGrowth Capital microsite
Allen & Overy is an engaged and active player in the growth company ecosystem.
Go to micrositeDownload our sector brochure
Our Life Sciences and Healthcare sector focus 2022
Related content
Global trends in merger control enforcement
Record levels in the first half of 2018 and considerable contraction in the second.